Ticker Details
Zymeworks Inc. Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer.
IPO Date:	April 28, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.03B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.45 | 2.57%
Avg Daily Range (30 D):	$0.46 | 1.87%
Avg Daily Range (90 D):	$0.46 | 1.88%

Institutional Daily Volume
Avg Daily Volume:	.45M
Avg Daily Volume (30 D):	.59M
Avg Daily Volume (90 D):	.6M

Trade Size
Avg Trade Size (Sh.):	95
Avg Trade Size (Sh.) (30 D):	44
Avg Trade Size (Sh.) (90 D):	52

Institutional Trades
Total Institutional Trades:	1,836
Avg Institutional Trade:	$1.77M
Avg Institutional Trade (30 D):	$2.37M
Avg Institutional Trade (90 D):	$1.94M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.46M
Avg Closing Trade (30 D):	$2.48M
Avg Closing Trade (90 D):	$2.16M
Avg Closing Volume:	99.74K

News

Apr 9, 2026 @ 10:00 AM Zymeworks Announces Additional Leadership Appointm... Source: Na

Apr 1, 2026 @ 10:00 AM Zymeworks Appoints Kristin Stafford as Chief Finan... Source: Na

Mar 30, 2026 @ 10:00 AM Zymeworks Receives U.S. FDA Fast Track Designation... Source: Na

Mar 24, 2026 @ 10:00 AM Zymeworks Announces Participation in Upcoming Inve... Source: Na

Feb 12, 2026 @ 11:00 AM Zymeworks To Report Fourth Quarter and Full Year 2... Source: Na

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-1.08	$-.55	$-1.08
Diluted EPS	$-1.08	$-.55	$-1.08
Revenue	$105.97M	$2.52M	$105.97M
Gross Profit
Net Income / Loss	$-81.13M	$-41.21M	$-81.13M
Operating Income / Loss	$-92.55M	$-44.15M	$-92.55M
Cost of Revenue
Net Cash Flow	$-24.95M	$-23.68M	$-24.95M
PE Ratio